A comprehensive review of clocortolone pivalate 0.1% cream: Structural development, formulation characteristics, and studies supporting treatment of corticosteroid-responsive dermatoses

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 7, 2012, Pages 20-24

  Del Rosso, James Q ^a   Kircik, Leon ^b  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOCORTOLONE PIVALATE; CORTICOSTEROID; DRUG VEHICLE; PLACEBO;

ACNE; APPLICATION SITE ATROPHY; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ATOPIC DERMATITIS; CATARACTOGENESIS; CONTACT DERMATITIS; CREAM; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; ECZEMA; FACE DISORDER; FOLLICULITIS; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INJECTION SITE STINGING; IRRITANT DERMATITIS; LICHEN PLANUS; LIPOPHILICITY; MONOTHERAPY; PEDIATRICS; PSORIASIS VULGARIS; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ALLERGY; SKIN BURNING SENSATION; SKIN DISEASE; SKIN FISSURE; SKIN INFLAMMATION; SKIN IRRITATION; SKIN SENSITIVITY; STRATUM CORNEUM; STRIA; TELANGIECTASIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866277295     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004;50:391-404. (Pubitemid 38324578)
2. Leung DYM, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Asthma Immunol. 2004;93:S1-S21. (Pubitemid 39274348)
3. Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36:563-577.
4. Bourke J, Coulson I, English J. Guidelines for the management of contact dermatitis: an update. Br J Dermatol. 2009;160:946-954.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
6. Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Therapy Lett. 2010;15(5):1-4.
7. Sapp BR, Moss PE, Davis RL. Topical corticosteroids: considerations for appropriate use. Am J Managed Care. 1999;5(6):787-792. (Pubitemid 29296032)
8. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids: a review. Drugs. 1988;36(suppl 5):51-61. (Pubitemid 19175860)
9. Cloderm [package insert]. Bridewater, New Jersey: Promius Pharma, LLC; 2011.
10. Data on file. Bridewater, New Jersey: Promius Pharma, LLC; 2011.
11. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5(2):125-130.
12. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1):S50-S58. (Pubitemid 40828181)
13. Magnusson BM, Cross SE, Winckle G, Roberts MS. Percutaneous absorption of steroids: determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol Physiol. 2006;19(6):336-342. (Pubitemid 44808088)
14. Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and developmenta process of "planned serendipity." J Pharm Sci. 2008;97(8):2936-2947.
15. Buchwald P. Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008;73(2):193-208.
16. Holden C, English J, Hoare C, et al. Advised best practice for the use of emollients in eczema and other dry skin conditions. J Dermatolog Treat. 2002;13(3):103-106.